# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 19, "Curr Med Res Opin .", "", 
1, PublicationYear, 20, 24, "2017", "", "<http://ctro/data#Publication_84903> <http://ctro/data#hasPublicationYear> \"2017\"."
8, Title, 122, 337, "A randomized clinical trial evaluating the efficacy and safety of the once - weekly dipeptidyl peptidase - 4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy .", "", "<http://ctro/data#Publication_84903> <http://ctro/data#hasTitle> \"A randomized clinical trial evaluating the efficacy and safety of the once - weekly dipeptidyl peptidase - 4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy .\"."
2, Randomized, 124, 134, "randomized", "", 
3, Frequency, 192, 205, "once - weekly", "", 
4, Omarigliptin, 241, 253, "omarigliptin", "", 
129, Precondition, 257, 335, "patients with type 2 diabetes inadequately controlled on metformin monotherapy", "", 
5, Type2Diabetes, 271, 286, "type 2 diabetes", "", 
7, Metformin, 314, 323, "metformin", "", 
9, Author, 338, 348, "Shankar RR", "", "<http://ctro/data#Publication_84903> <http://ctro/data#hasAuthor> \"Shankar RR\"."
10, Author, 357, 368, "Inzucchi SE", "", "<http://ctro/data#Publication_84903> <http://ctro/data#hasAuthor> \"Inzucchi SE\"."
11, Author, 377, 389, "Scarabello V", "", "<http://ctro/data#Publication_84903> <http://ctro/data#hasAuthor> \"Scarabello V\"."
12, Author, 398, 405, "Gantz I", "", "<http://ctro/data#Publication_84903> <http://ctro/data#hasAuthor> \"Gantz I\"."
13, Author, 414, 424, "Kaufman KD", "", "<http://ctro/data#Publication_84903> <http://ctro/data#hasAuthor> \"Kaufman KD\"."
14, Author, 433, 438, "Lai E", "", "<http://ctro/data#Publication_84903> <http://ctro/data#hasAuthor> \"Lai E\"."
15, Author, 447, 455, "Ceesay P", "", "<http://ctro/data#Publication_84903> <http://ctro/data#hasAuthor> \"Ceesay P\"."
16, Author, 464, 477, "Suryawanshi S", "", "<http://ctro/data#Publication_84903> <http://ctro/data#hasAuthor> \"Suryawanshi S\"."
17, Author, 486, 494, "Engel SS", "", "<http://ctro/data#Publication_84903> <http://ctro/data#hasAuthor> \"Engel SS\"."
18, USA, 573, 576, "USA", "", "<http://ctro/data#Population_84937> <http://ctro/data#hasCountry> <http://ctro/data#USA>."
19, USA, 708, 711, "USA", "", 
27, ObjectiveDescription, 726, 793, "To examine the efficacy and safety of the once - weekly ( q . w . )", "", "<http://ctro/data#ClinicalTrial_84918> <http://ctro/data#hasObjectiveDescription> \"To examine the efficacy and safety of the once - weekly ( q . w . )\"."
20, Frequency, 768, 781, "once - weekly", "", "<http://ctro/data#Intervention_84984> <http://ctro/data#hasFrequency> \"once - weekly\". <http://ctro/data#Intervention_85004> <http://ctro/data#hasFrequency> \"once - weekly\"."
21, Frequency, 784, 791, "q . w .", "", 
28, ObjectiveDescription, 794, 946, "dipeptidyl peptidase - 4 inhibitor , omarigliptin , in patients with type 2 diabetes ( T2DM ) and inadequate glycemic control on metformin monotherapy .", "", "<http://ctro/data#ClinicalTrial_84918> <http://ctro/data#hasObjectiveDescription> \"dipeptidyl peptidase - 4 inhibitor , omarigliptin , in patients with type 2 diabetes ( T2DM ) and inadequate glycemic control on metformin monotherapy .\"."
22, Omarigliptin, 831, 843, "omarigliptin", "", 
146, Precondition, 849, 944, "patients with type 2 diabetes ( T2DM ) and inadequate glycemic control on metformin monotherapy", "", 
23, Type2Diabetes, 863, 878, "type 2 diabetes", "", "<http://ctro/data#ClinicalTrial_84918> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
24, Type2Diabetes, 881, 885, "T2DM", "", 
26, Metformin, 923, 932, "metformin", "", 
29, Randomized, 962, 972, "randomized", "", "<http://ctro/data#ClinicalTrial_84918> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
30, DoubleBlind, 975, 989, "double - blind", "", "<http://ctro/data#ClinicalTrial_84918> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
156, Precondition, 998, 1135, "patients with T2DM on a stable dose of metformin monotherapy ( ≥ 1500   mg / day ) with glycated hemoglobin ( HbA1c ) of 7 . 0 - 10 . 5 %", "", "<http://ctro/data#Population_84937> <http://ctro/data#hasPrecondition> \"patients with T2DM on a stable dose of metformin monotherapy ( ≥ 1500   mg / day ) with glycated hemoglobin ( HbA1c ) of 7 . 0 - 10 . 5 %\"."
31, Type2Diabetes, 1012, 1016, "T2DM", "", 
43, Precondition, 1017, 1080, "on a stable dose of metformin monotherapy ( ≥ 1500   mg / day )", "", 
32, Metformin, 1037, 1046, "metformin", "", 
151, DoseValue, 1061, 1067, "≥ 1500", "", 
152, mg, 1070, 1072, "mg", "", 
99456, Interval, 1075, 1078, "day", "", 
35, HbA1c, 1086, 1105, "glycated hemoglobin", "", 
36, HbA1c, 1108, 1113, "HbA1c", "", 
99449, Percentage, 1134, 1135, "%", "", 
38, Randomized, 1141, 1151, "randomized", "", 
39, Omarigliptin, 1155, 1167, "omarigliptin", "", "<http://ctro/data#Medication_84990> <http://ctro/data#hasDrug> <http://ctro/data#Omarigliptin>."
158, DoseValue, 1168, 1170, "25", "", "<http://ctro/data#Medication_84990> <http://ctro/data#hasDoseValue> \"25\". <http://ctro/data#Medication_84997> <http://ctro/data#hasDoseValue> \"25\"."
41, mg, 1173, 1175, "mg", "", "<http://ctro/data#Medication_84990> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>. <http://ctro/data#Medication_84997> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>."
42, Frequency, 1176, 1183, "q . w .", "", 
45, Placebo, 1196, 1203, "placebo", "", "<http://ctro/data#Medication_84997> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
46, NumberPatientsArm, 1212, 1215, "201", "", "<http://ctro/data#Arm_85010> <http://ctro/data#hasNumberPatientsArm> \"201\"."
47, Duration, 1230, 1238, "24 weeks", "", "<http://ctro/data#ClinicalTrial_84918> <http://ctro/data#hasCTduration> \"24 weeks\"."
48, Duration, 1287, 1296, "80 - week", "", 
49, TimePoint, 1329, 1336, "week 24", "", "<http://ctro/data#Outcome_85019> <http://ctro/data#hasTimePoint> \"week 24\". <http://ctro/data#Outcome_85046> <http://ctro/data#hasTimePoint> \"week 24\"."
51, Mean, 1346, 1350, "mean", "", 
50, TimePoint, 1351, 1359, "baseline", "", 
52, HbA1c, 1360, 1365, "HbA1c", "", "<http://ctro/data#Endpoint_84945> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
66, BaseLineValue, 1369, 1382, "8 . 0 - 8 . 1", "", "<http://ctro/data#Outcome_85019> <http://ctro/data#hasBaselineValue> \"8 . 0 - 8 . 1\". <http://ctro/data#Outcome_85046> <http://ctro/data#hasBaselineValue> \"8 . 0 - 8 . 1\"."
54, Percentage, 1383, 1384, "%", "", "<http://ctro/data#Endpoint_84945> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
67, LeastSquaresMean, 1391, 1416, "least squares ( LS ) mean", "", "<http://ctro/data#Endpoint_84945> <http://ctro/data#hasAggregationMethod> <http://ctro/data#LeastSquaresMean>."
68, TimePoint, 1441, 1449, "baseline", "", 
53, HbA1c, 1453, 1458, "HbA1c", "", "<http://ctro/data#Endpoint_84945> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
176, Reduction, 1489, 1495, "0 . 54", "", "<http://ctro/data#Outcome_85019> <http://ctro/data#hasChangeValue> \"0 . 54\"."
64, Percentage, 1496, 1497, "%", "", 
72, ConfIntervalChangeValue, 1500, 1523, "- 0 . 69 % , - 0 . 40 %", "", "<http://ctro/data#Outcome_85019> <http://ctro/data#hasConfIntervalChangeValue> \"- 0 . 69 % , - 0 . 40 %\"."
99458, Percentage, 1509, 1510, "%", "", 
99459, Percentage, 1522, 1523, "%", "", 
77, Omarigliptin, 1533, 1545, "omarigliptin", "", 
99457, Reduction, 1556, 1562, "0 . 00", "", "<http://ctro/data#Outcome_85046> <http://ctro/data#hasChangeValue> \"0 . 00\"."
61, Percentage, 1563, 1564, "%", "", 
73, ConfIntervalChangeValue, 1567, 1588, "- 0 . 14 % , 0 . 15 %", "", "<http://ctro/data#Outcome_85046> <http://ctro/data#hasConfIntervalChangeValue> \"- 0 . 14 % , 0 . 15 %\"."
99460, Percentage, 1576, 1577, "%", "", 
59, Percentage, 1587, 1588, "%", "", 
76, Placebo, 1598, 1605, "placebo", "", 
71, DiffGroupAbsValue, 1650, 1658, "- 0 . 55", "", "<http://ctro/data#DiffBetweenGroups_85073> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 55\"."
58, Percentage, 1659, 1660, "%", "", 
74, ConfIntervalDiff, 1663, 1686, "- 0 . 75 % , - 0 . 34 %", "", "<http://ctro/data#DiffBetweenGroups_85073> <http://ctro/data#hasConfIntervalDiff> \"- 0 . 75 % , - 0 . 34 %\"."
57, Percentage, 1672, 1673, "%", "", 
56, Percentage, 1685, 1686, "%", "", 
75, PvalueDiff, 1691, 1701, "p  < . 001", "", "<http://ctro/data#DiffBetweenGroups_85073> <http://ctro/data#hasPvalueDiff> \"p  < . 001\"."
78, LeastSquaresMean, 1734, 1741, "LS mean", "", "<http://ctro/data#Endpoint_84950> <http://ctro/data#hasAggregationMethod> <http://ctro/data#LeastSquaresMean>. <http://ctro/data#Endpoint_84955> <http://ctro/data#hasAggregationMethod> <http://ctro/data#LeastSquaresMean>."
197, PostprandialBloodGlucose, 1786, 1811, "2 - h post - meal glucose", "", "<http://ctro/data#Endpoint_84950> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#PostprandialBloodGlucose>."
80, FastingPlasmaGlucose, 1816, 1838, "fasting plasma glucose", "", "<http://ctro/data#Endpoint_84955> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#FastingPlasmaGlucose>."
81, Omarigliptin, 1841, 1853, "omarigliptin", "", 
82, Placebo, 1857, 1864, "placebo", "", 
83, DiffGroupAbsValue, 1872, 1879, "- 0 . 8", "", "<http://ctro/data#DiffBetweenGroups_85190> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 8\"."
85, Millimoles_per_litre, 1882, 1890, "mmol / L", "", "<http://ctro/data#Endpoint_84950> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Millimoles_per_litre>."
87, ConfIntervalDiff, 1893, 1910, "- 1 . 4 , - 0 . 2", "", "<http://ctro/data#DiffBetweenGroups_85190> <http://ctro/data#hasConfIntervalDiff> \"- 1 . 4 , - 0 . 2\"."
89, PvalueDiff, 1915, 1925, "p  = . 011", "", "<http://ctro/data#DiffBetweenGroups_85190> <http://ctro/data#hasPvalueDiff> \"p  = . 011\"."
84, DiffGroupAbsValue, 1932, 1939, "- 0 . 5", "", "<http://ctro/data#DiffBetweenGroups_85199> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 5\"."
86, Millimoles_per_litre, 1940, 1948, "mmol / L", "", "<http://ctro/data#Endpoint_84955> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Millimoles_per_litre>."
88, ConfIntervalDiff, 1951, 1968, "- 0 . 9 , - 0 . 1", "", "<http://ctro/data#DiffBetweenGroups_85199> <http://ctro/data#hasConfIntervalDiff> \"- 0 . 9 , - 0 . 1\"."
90, PvalueDiff, 1973, 1983, "p  = . 010", "", "<http://ctro/data#DiffBetweenGroups_85199> <http://ctro/data#hasPvalueDiff> \"p  = . 010\"."
91, TimePoint, 2006, 2013, "week 24", "", 
92, SymptomaticHypoglycemia, 2034, 2058, "symptomatic hypoglycemia", "", "<http://ctro/data#Endpoint_84960> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#SymptomaticHypoglycemia>."
210, EndPointDescription, 2089, 2102, "adverse event", "", "<http://ctro/data#EndPointDescription_84966> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_84965> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_84966>."
211, EndPointDescription, 2105, 2107, "AE", "", 
212, EndPointDescription, 2112, 2123, "serious AEs", "", "<http://ctro/data#EndPointDescription_84971> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_84970> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_84971>."
99461, ObservedResult, 2160, 2211, "were similar in the omarigliptin and placebo groups", "", "<http://ctro/data#Outcome_85208> <http://ctro/data#hasObservedResult> \"were similar in the omarigliptin and placebo groups\". <http://ctro/data#Outcome_85235> <http://ctro/data#hasObservedResult> \"were similar in the omarigliptin and placebo groups\". <http://ctro/data#Outcome_85262> <http://ctro/data#hasObservedResult> \"were similar in the omarigliptin and placebo groups\"."
93, Omarigliptin, 2180, 2192, "omarigliptin", "", 
94, Placebo, 2197, 2204, "placebo", "", 
95, TimePoint, 2219, 2228, "104 weeks", "", 
217, ObservedResult, 2231, 2305, "omarigliptin treatment provided a clinically meaningful reduction in HbA1c", "", 
96, Omarigliptin, 2231, 2243, "omarigliptin", "", 
97, HbA1c, 2300, 2305, "HbA1c", "", 
106, ConclusionComment, 2322, 2381, "In patients with T2DM , adding omarigliptin 25   mg q . w .", "", "<http://ctro/data#ClinicalTrial_84918> <http://ctro/data#hasConclusionComment> \"In patients with T2DM , adding omarigliptin 25   mg q . w .\"."
98, Type2Diabetes, 2339, 2343, "T2DM", "", 
99, Omarigliptin, 2353, 2365, "omarigliptin", "", 
218, DoseValue, 2366, 2368, "25", "", 
101, mg, 2371, 2373, "mg", "", 
102, Frequency, 2374, 2381, "q . w .", "", 
107, ConclusionComment, 2382, 2513, "to metformin monotherapy improved glycemic control over 104 weeks and was generally welltolerated with a low risk of hypoglycemia .", "", "<http://ctro/data#ClinicalTrial_84918> <http://ctro/data#hasConclusionComment> \"to metformin monotherapy improved glycemic control over 104 weeks and was generally welltolerated with a low risk of hypoglycemia .\"."
103, Metformin, 2385, 2394, "metformin", "", 
104, Duration, 2438, 2447, "104 weeks", "", 
105, Hypoglycemia, 2499, 2511, "hypoglycemia", "", 
108, PMID, 2565, 2573, "28547998", "", "<http://ctro/data#Publication_84903> <http://ctro/data#hasPMID> \"28547998\"."
